Clinical Trial

Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer

Study acronym: Bioblation
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 13, 2026 (before its estimated April 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
This prospective study aims to validate the clinical outcomes of performing a concomitant trans-perineal prostate biopsy and laser ablation (termed "Bioblation") during a single session. The intervention is designed for symptomatic patients presenting with lower urinary tract symptoms (LUTS) who are highly suspected to have low to favorable intermediate-risk prostate cancer. By combining diagnosis and targeted treatment under local anesthesia, this approach seeks to facilitate early relief of severe symptoms and a rapid return to daily activities. Ultimately, the study evaluates whether this combined procedure decreases the patient's exposure to multiple, temporally separated interventions without compromising oncological safety or efficacy.
Trial Details
NCT Number NCT07526675
Lead Sponsor Benha University
Conditions Prostate Cancer, Lower Urinary Tract Symptoms (LUTS), Benign Prostatic Hyperplasia
Enrollment 30 participants
Start Date 2026-04-10
Primary Completion 2026-04-20 (estimated)
Study Completion 2026-04-28 (estimated)
Updated on ClinicalTrials.gov 2026-04-13